Navigation Links
Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Date:2/5/2008

SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) will announce financial results for the fourth quarter and year ended 2007 after the markets close on Monday, February 11, 2007 and will hold a webcast teleconference at 4:30 p.m. EDT that day. Members of Anesiva's management team will discuss financial results from the fourth quarter and full year 2007 as well as provide an overview of the company's product pipeline, recent events and milestones.

Interested parties can listen to the live audio webcast by dialing (800) 340-6289 (international dial: (706) 634-1538) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing (800) 642-1687 (international dial: 706-645-9291) and giving the following pass code: 31729950. The webcast will be available until the company's next quarterly financial results conference call.

Anesiva further announced that company management will present at the following events in February 2008:

-- BIO CEO & Investor Conference

Feb. 13, 2008 1:15 p.m. Eastern Time

Presentation:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ANSV&item_id=1 752218

-- Roth Capital Partners 20th Annual Growth Stock Conference

Feb. 21, 2008 9 a.m. Pacific Time

Presentation: http://www.rothcp.com/main/Page.aspx?PageID=7010

Live audio webcasts of the presentations will also be available online via the Investor Relations portion of Anesiva's website at http://www.anesiva.com. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and NEW YORK , Feb. ... Lumeon , a leading digital health company, and ... provider of telemedicine and remote patient monitoring, announce ... telemedicine reimbursements.  DN Telehealth maximizes ... in real-time, extending consultations beyond a physical clinical ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® ... adults at home or in healthcare facilities during periods of rest. A lightweight, ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc ... with Compass Research . GGI's mission is to advance global health and highlight ... in need in honor of each clinical trial volunteer. The vision of GGI is ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):